Programs currently tracked for this institution in the public Translational Deal Radar dataset.
Dual-target CAR-NK cells is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a probable patent signal linked through target_match, modality_match. Manual review is still required.
Phase1 · Recruiting
View assetEB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Recruiting
View assetEB-DT-NK-UC101 is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Recruiting
View assetEB-DT-CAR-NK is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Recruiting
View assetEB-DUALNK is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Recruiting
View assetEB-DUO-CAR-NK-CEA/GCC is flagged as a partnering watch because it has an active early-phase oncology cell-therapy trial at Beijing Biotech, with a possible patent signal linked through modality_match. Manual review is still required.
Phase1 · Recruiting
View asset